**Figure 1: PRISMA flowchart**

****

**Table 1: Extracted dataset entered final analysis**

<https://osf.io/m3dsy/>

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Study****ID** | **Study** | **Full\_Code** | **N** | **CtrlN** | **Comorb** | **Adv** | **OR** | **CIL** | **CIU** | **P** | **OR\_Mthd** | **SE** | **Qlty** | **Dsgn** | **AV\_Msur** | **PD\_Msur** |
| 1 | Afifi (2014) | Afifi (2014) - ANY AB | 23395 | NA | N | ANY AB | 2.2 | 1.7 | 2.8 | NA | RGS | 0.12729367 | 2 | CS | CEVQ | DSM-IV |
| 1 | Afifi (2014) | Afifi (2014) - PA | 23395 | NA | N | PA | 2.2 | 1.7 | 2.7 | NA | RGS | 0.11801621 | 2 | CS | CEVQ | DSM-IV |
| 1 | Afifi (2014) | Afifi (2014) - SA | 23395 | NA | N | SA | 2.9 | 2.3 | 3.7 | NA | RGS | 0.12128156 | 2 | CS | CEVQ | DSM-IV |
| 1 | Afifi (2014) | Afifi (2014) - DV | 23395 | NA | N | DV | 1.8 | 1.3 | 2.3 | NA | RGS | 0.14554716 | 2 | CS | CEVQ | DSM-IV |
| 6 | Asselmann (2017) | Asselmann (2017) - HSSL | 2797 | NA | N | HSSL | 1.4 | 1 | 1.9 | NA | RGS | 0.16373824 | 1 | LG | DHS | ICD-10, DSM-IV |
| 3 | Asselmann (2018) | Asselmann (2018) - EA | 2263 | NA | N | EA | 1.18 | 1.12 | 1.24 | NA | RGS | 0.02596497 | 1 | CS | CTQ | ICD-10, DSM-IV |
| 3 | Asselmann (2018) | Asselmann (2018) - PA | 2263 | NA | N | PA | 1.13 | 1.06 | 1.21 | NA | RGS | 0.03376313 | 1 | CS | CTQ | ICD-10, DSM-IV |
| 3 | Asselmann (2018) | Asselmann (2018) - SA | 2263 | NA | N | SA | 1.08 | 1 | 1.18 | NA | RGS | 0.04222307 | 1 | CS | CTQ | ICD-10, DSM-IV |
| 3 | Asselmann (2018) | Asselmann (2018) - EN | 2263 | NA | N | EN | 1.1 | 1.06 | 1.15 | NA | RGS | 0.02078904 | 1 | CS | CTQ | ICD-10, DSM-IV |
| 3 | Asselmann (2018) | Asselmann (2018) - PN | 2263 | NA | N | PN | 1.08 | 1 | 1.16 | NA | RGS | 0.03786225 | 1 | CS | CTQ | ICD-10, DSM-IV |
| 5 | Asselmann (2018) 2 | Asselmann (2018) 2 - ANY AB | 199 | 198 | N | ANY AB | 1.12 | 1.03 | 1.21 | NA | RGS | 0.04108713 | 2 | CC | CTQ | ICD-10, DSM-IV |
| 5 | Asselmann (2018) 2 | Asselmann (2018) 2 - EA | 199 | 198 | N | EA | 1.36 | 1.12 | 1.66 | NA | RGS | 0.10037983 | 2 | CC | CTQ | ICD-10, DSM-IV |
| 5 | Asselmann (2018) 2 | Asselmann (2018) 2 - PA | 199 | 198 | N | PA | 1.27 | 1.03 | 1.57 | NA | RGS | 0.1075298 | 2 | CC | CTQ | ICD-10, DSM-IV |
| 5 | Asselmann (2018) 2 | Asselmann (2018) 2 - SA | 199 | 198 | N | SA | 1.05 | 0.89 | 1.23 | NA | RGS | 0.08253775 | 2 | CC | CTQ | ICD-10, DSM-IV |
| 5 | Asselmann (2018) 2 | Asselmann (2018) 2 - ANY NG | 199 | 198 | N | ANY NG | 1.19 | 1.08 | 1.3 | NA | RGS | 0.04729674 | 2 | CC | CTQ | ICD-10, DSM-IV |
| 5 | Asselmann (2018) 2 | Asselmann (2018) 2 - EN | 199 | 198 | N | EN | 1.3 | 1.13 | 1.49 | NA | RGS | 0.07055063 | 2 | CC | CTQ | ICD-10, DSM-IV |
| 5 | Asselmann (2018) 2 | Asselmann (2018) 2 - PN | 199 | 198 | N | PN | 1.23 | 1.04 | 1.44 | NA | RGS | 0.08301592 | 2 | CC | CTQ | ICD-10, DSM-IV |
| 7 | Bandelow (2002) | Bandelow (2002) - FAD | 115 | 124 | N | FAD | 4.25 | NA | NA | 0.008 | RGS | 0.54558103 | 2 | CC | QwR | DSM-IV |
| 7 | Bandelow (2002) | Bandelow (2002) - STE | 115 | 124 | N | STE | 1.58 | NA | NA | 0.009 | RGS | 0.17512074 | 2 | CC | QwR | DSM-IV |
| 8 | Bidaut-Russell (1994) | Bidaut-Russell (1994) - PAL | 29 | 326 | N | PAL | 2.86 | 0.31 | 26.52 | NA | RGS | 1.13496994 | 2 | CC/PRS | QbS | DSM-III-R |
| 14 | Copeland (2010) | Copeland (2010) - PA | 4141 | NA | N | PA | 1.46 | 1.08 | 1.98 | NA | RGS | 0.15462648 | 2 | CS | QwR | DSM-IV |
| 14 | Copeland (2010) | Copeland (2010) - SA | 4141 | NA | N | SA | 2.1 | 1.46 | 3.03 | NA | RGS | 0.18625668 | 2 | CS | QwR | DSM-IV |
| 13 | Copeland (2013) | Copeland (2013) - ANY BL | 1420 | NA | N | ANY BL | 14.5 | 5.7 | 36.6 | NA | RGS | 0.47438318 | 2 | CH/PRS | QwR | DSM-IV |
| 13 | Copeland (2013) | Copeland (2013) - BLPP | 1420 | NA | N | BLPP | 1.6 | 0.5 | 4.8 | NA | RGS | 0.57698038 | 2 | CH/PRS | QwR | DSM-IV |
| 13 | Copeland (2013) | Copeland (2013) - BLVM | 1420 | NA | N | BLVM | 3.1 | 1.5 | 6.5 | NA | RGS | 0.37406558 | 2 | CH/PRS | QwR | DSM-IV |
| 15 | Dinwiddie (2000) - F | Dinwiddie (2000) - F - SA | 3868 | NA | N | SA | 3.54 | 2.92 | 5.47 | NA | RGS | 0.16012628 | 3 | CS | QwR | DSM-III-R |
| 15 | Dinwiddie (2000) - M | Dinwiddie (2000) - M - SA | 2078 | NA | N | SA | 5.02 | 1.9 | 13.25 | NA | RGS | 0.49544481 | 3 | CS | QwR | DSM-III-R |
| 16 | El-Guebaly et al. (1991) | El-Guebaly et al. (1991) - PAL | 250 | 170 | Y | PAL | 2 | 0.9 | 4.44 | NA | CONT | 0.40714666 | 2 | CC | CAST | DSM-III |
| 21 | Goodwin (2005) | Goodwin (2005) - PA | 983 | NA | N | PA | 3 | 1.1 | 7.9 | NA | RGS | 0.50294709 | 1 | CS | QwR | DSM-IV |
| 21 | Goodwin (2005) | Goodwin (2005) - SA | 983 | NA | N | SA | 2.2 | 0.98 | 5 | NA | RGS | 0.41572465 | 1 | CS | QwR | DSM-IV |
| 21 | Goodwin (2005) | Goodwin (2005) - DV | 983 | NA | N | DV | 1.8 | 0.7 | 4.4 | NA | RGS | 0.46894885 | 1 | CS | QwR | DSM-IV |
| 22 | Goodwin (2005) | Goodwin (2005) - FAD | 940 | NA | N | FAD | 6.3 | 2.6 | 15.5 | NA | RGS | 0.45544096 | 1 | LG/PRS | QbS | DSM-IV |
| 27 | Jonas (2010) | Jonas (2010) - SA | 7353 | NA | N | SA | 1.6 | 1.3 | 2 | NA | RGS | 0.1098936 | 2 | CS | QwR | CIS-R |
| 28 | Keyes (2014) - 10-14 yrs | Keyes (2014) - 10-14 yrs - LOSS | 27534 | NA | N | LOSS | 2.08 | 1.08 | 4.02 | NA | RGS | 0.33528593 | 1 | CS | QwR | DSM-IV |
| 28 | Keyes (2014) - 15-19 yrs | Keyes (2014) - 15-19 yrs - LOSS | 27534 | NA | N | LOSS | 1.57 | 1.1 | 2.24 | NA | RGS | 0.18141982 | 1 | CS | QwR | DSM-IV |
| 28 | Keyes (2014) - 5-9 yrs | Keyes (2014) - 5-9 yrs - LOSS | 27534 | NA | N | LOSS | 3.64 | 1.56 | 8.5 | NA | RGS | 0.43249499 | 1 | CS | QwR | DSM-IV |
| 29 | Leen-Feldner et al. (2011) | #REF! | 3931 | NA | N | PPD | 5.30 | 3.74 | 7.52 | NA | CONT | #REF! | 3 | CS | QbS | DSM-IV |
| 30 | Kraan et al. (2018) | Kraan et al. (2018) - EA | 259 | 48 | N | EA | 0.81 | 0.4 | 1.65 | NA | RGS | 0.36149643 | 2 | CC | CTQ | DSM-IV |
| 30 | Kraan et al. (2018) | Kraan et al. (2018) - PA | 259 | 48 | N | PA | 2 | 1 | 3.99 | NA | RGS | 0.35300797 | 2 | CC | CTQ | DSM-IV |
| 30 | Kraan et al. (2018) | Kraan et al. (2018) - SA | 259 | 48 | N | SA | 0.85 | 0.46 | 1.58 | NA | RGS | 0.31478409 | 2 | CC | CTQ | DSM-IV |
| 30 | Kraan et al. (2018) | Kraan et al. (2018) - ANY AB | 259 | 48 | N | ANY AB | 0.64 | 0.35 | 1.19 | NA | RGS | 0.31218761 | 2 | CC | CTQ | DSM-IV |
| 30 | Kraan et al. (2018) | Kraan et al. (2018) - EN | 259 | 48 | N | EN | 0.67 | 0.3 | 1.49 | NA | RGS | 0.40886452 | 2 | CC | CTQ | DSM-IV |
| 30 | Kraan et al. (2018) | Kraan et al. (2018) - PN | 259 | 48 | N | PN | 1.31 | 0.69 | 2.46 | NA | RGS | 0.3242921 | 2 | CC | CTQ | DSM-IV |
| 29 | Leen-Feldner et al. (2011) | Leen-Feldner et al. (2011) - PPD | 3931 | NA | N | PPD | 5.3 | 3.74 | 7.52 | NA | CONT | 0.17818381 | 3 | CS | QwR | DSM-IV |
| 31 | Libby et al. (2005) - N | Libby et al. (2005) - N - PA | 1638 | NA | N | PA | 2.88 | NA | NA | NA | RGS | 1.07 | 2 | CS | QwR | DSM-IV |
| 31 | Libby et al. (2005) - N | Libby et al. (2005) - N - SA | 1638 | NA | N | SA | 1.4 | NA | NA | NA | RGS | 0.87 | 2 | CS | QwR | DSM-IV |
| 31 | Libby et al. (2005) - S | Libby et al. (2005) - S - PA | 1446 | NA | N | PA | 3.35 | NA | NA | NA | RGS | 1.03 | 2 | CS | QwR | DSM-IV |
| 31 | Libby et al. (2005) - S | Libby et al. (2005) - S - SA | 1446 | NA | N | SA | 4.41 | NA | NA | NA | RGS | 1.45 | 2 | CS | QwR | DSM-IV |
| 34 | MacPherson et al. (2001) | MacPherson et al. (2001) - PAL | 213 | NA | N | PAL | 2.5 | NA | NA | SE = B/t | RGS | 0.556 | 3 | CS | CAST | PAQ-R |
| 36 | Mathew et al. (1993) | Mathew et al. (1993) - PAL | 1885 | 1447 | N | PAL | 4.06 | NA | NA | 0.01 | RGS | 0.54397354 | 2 | CC | QwR | DSM-III |
| 39 | Morgan et al. (2010) - F | Morgan et al. (2010) - F - PAL | 40374 | NA | N | PAL | 1.73 | NA | NA | 0.0001 | RGS | 0.14088381 | 2 | CS | QwR | DSM-IV |
| 39 | Morgan et al. (2010) - M | Morgan et al. (2010) - M - PAL | 40374 | NA | N | PAL | 1.61 | NA | NA | 0.0001 | RGS | 0.12240661 | 2 | CS | QwR | DSM-IV |
| 40 | Murrey et al. (1993) | Murrey et al. (1993) - SA | 185 | NA | Y | SA | 1.1 | 0.37 | 3.29 | NA | CONT | 0.55743363 | 2 | CS | QwR | DSM-III-R |
| 41 | Otowa et al. (2014) | Otowa et al. (2014) - LOSS | 2605 | NA | N | LOSS | 0.78 | 0.24 | 2.52 | NA | RGS | 0.59984063 | 1 | CS | QwR | DSM-III-R |
| 41 | Otowa et al. (2014) | Otowa et al. (2014) - SPT | 2605 | NA | N | SPT | 2.01 | 1.09 | 3.72 | NA | RGS | 0.31314948 | 1 | CS | QwR | DSM-III-R |
| 42 | Pavlova et al. (2016) | Pavlova et al. (2016) - EA | 174 | NA | Y | EA | 1.75 | 0.99 | 3.12 | NA | RGS | 0.29282738 | 1 | CS | CTQ | DSM-IV-TR |
| 42 | Pavlova et al. (2016) | Pavlova et al. (2016) - PA | 174 | NA | Y | PA | 1.66 | 1.07 | 2.56 | NA | RGS | 0.22253791 | 1 | CS | CTQ | DSM-IV-TR |
| 42 | Pavlova et al. (2016) | Pavlova et al. (2016) - SA | 174 | NA | Y | SA | 1.52 | 0.96 | 2.42 | NA | RGS | 0.23586468 | 1 | CS | CTQ | DSM-IV-TR |
| 42 | Pavlova et al. (2016) | Pavlova et al. (2016) - EN | 174 | NA | Y | EN | 1.68 | 0.96 | 2.92 | NA | RGS | 0.28377694 | 1 | CS | CTQ | DSM-IV-TR |
| 42 | Pavlova et al. (2016) | Pavlova et al. (2016) - PN | 174 | NA | Y | PN | 2.02 | 1.2 | 3.4 | NA | RGS | 0.26567701 | 1 | CS | CTQ | DSM-IV-TR |
| 44 | Sareen et al. (2013) - F | Sareen et al. (2013) - F - PA | 8340 | NA | N | PA | 1.89 | 1.13 | 3.17 | NA | RGS | 0.26314132 | 1 | CS | QwR | DSM-IV |
| 44 | Sareen et al. (2013) - F | Sareen et al. (2013) - F - SA | 8340 | NA | N | SA | 1.25 | 0.73 | 2.12 | NA | RGS | 0.27197113 | 1 | CS | QwR | DSM-IV |
| 44 | Sareen et al. (2013) - F | Sareen et al. (2013) - F - PAL | 8340 | NA | N | PAL | 1.7 | 1.23 | 2.34 | NA | RGS | 0.1640655 | 1 | CS | QwR | DSM-IV |
| 44 | Sareen et al. (2013) - F | Sareen et al. (2013) - F - SPT | 8340 | NA | N | SPT | 1.1 | 0.79 | 1.53 | NA | RGS | 0.16861992 | 1 | CS | QwR | DSM-IV |
| 44 | Sareen et al. (2013) - F | Sareen et al. (2013) - F - CP | 8340 | NA | N | CP | 1.19 | 0.41 | 3.47 | NA | RGS | 0.54483488 | 1 | CS | QwR | DSM-IV |
| 44 | Sareen et al. (2013) - F | Sareen et al. (2013) - F - DV | 8340 | NA | N | DV | 1.49 | 1.01 | 2.19 | NA | RGS | 0.19743653 | 1 | CS | QwR | DSM-IV |
| 44 | Sareen et al. (2013) - F | Sareen et al. (2013) - F - ED | 8340 | NA | N | ED | 1.49 | 1.05 | 2.13 | NA | RGS | 0.18044179 | 1 | CS | QwR | DSM-IV |
| 44 | Sareen et al. (2013) - M | Sareen et al. (2013) - M - PA | 8340 | NA | N | PA | 1.7 | 1.14 | 2.54 | NA | RGS | 0.20437138 | 1 | CS | QwR | DSM-IV |
| 44 | Sareen et al. (2013) - M | Sareen et al. (2013) - M - SA | 8340 | NA | N | SA | 1.25 | 0.44 | 3.55 | NA | RGS | 0.53263473 | 1 | CS | QwR | DSM-IV |
| 44 | Sareen et al. (2013) - M | Sareen et al. (2013) - M - PAL | 8340 | NA | N | PAL | 1.23 | 0.94 | 1.61 | NA | RGS | 0.13727285 | 1 | CS | QwR | DSM-IV |
| 44 | Sareen et al. (2013) - M | Sareen et al. (2013) - M - SPT | 8340 | NA | N | SPT | 1.3 | 1 | 1.7 | NA | RGS | 0.13536435 | 1 | CS | QwR | DSM-IV |
| 44 | Sareen et al. (2013) - M | Sareen et al. (2013) - M - CP | 8340 | NA | N | CP | 1.18 | 0.49 | 2.79 | NA | RGS | 0.44372232 | 1 | CS | QwR | DSM-IV |
| 44 | Sareen et al. (2013) - M | Sareen et al. (2013) - M - DV | 8340 | NA | N | DV | 1.48 | 1.07 | 2.04 | NA | RGS | 0.16461509 | 1 | CS | QwR | DSM-IV |
| 44 | Sareen et al. (2013) - M | Sareen et al. (2013) - M - ED | 8340 | NA | N | ED | 1.06 | 0.78 | 1.44 | NA | RGS | 0.1564042 | 1 | CS | QwR | DSM-IV |
| 45 | Seganfredo et al. (2009) - F | Seganfredo et al. (2009) - F - EA | 246 | 123 | Y | EA | 2.66 | 1.42 | 4.97 | NA | RGS | 0.31958239 | 1 | CC | CTQ | DSM-IV |
| 45 | Seganfredo et al. (2009) - F | Seganfredo et al. (2009) - F - PA | 246 | 123 | Y | PA | 2.52 | 1.32 | 4.78 | NA | RGS | 0.32826755 | 1 | CC | CTQ | DSM-IV |
| 45 | Seganfredo et al. (2009) - F | Seganfredo et al. (2009) - F - SA | 246 | 123 | Y | SA | 2.4 | 0.98 | 5.9 | NA | RGS | 0.45794772 | 1 | CC | CTQ | DSM-IV |
| 45 | Seganfredo et al. (2009) - F | Seganfredo et al. (2009) - F - EN | 246 | 123 | Y | EN | 2.96 | 1.6 | 5.49 | NA | RGS | 0.31452159 | 1 | CC | CTQ | DSM-IV |
| 45 | Seganfredo et al. (2009) - F | Seganfredo et al. (2009) - F - PN | 246 | 123 | Y | PN | 1.77 | 0.96 | 3.24 | NA | RGS | 0.31030493 | 1 | CC | CTQ | DSM-IV |
| 45 | Seganfredo et al. (2009) - M | Seganfredo et al. (2009) - M - EA | 246 | 123 | Y | EA | 2.81 | 1.08 | 7.47 | NA | RGS | 0.4933505 | 1 | CC | CTQ | DSM-IV |
| 45 | Seganfredo et al. (2009) - M | Seganfredo et al. (2009) - M - PA | 246 | 123 | Y | PA | 2.03 | 0.78 | 5.34 | NA | RGS | 0.49073648 | 1 | CC | CTQ | DSM-IV |
| 45 | Seganfredo et al. (2009) - M | Seganfredo et al. (2009) - M - SA | 246 | 123 | Y | SA | 1.5 | 0.43 | 5.25 | NA | RGS | 0.63831585 | 1 | CC | CTQ | DSM-IV |
| 45 | Seganfredo et al. (2009) - M | Seganfredo et al. (2009) - M - EN | 246 | 123 | Y | EN | 2.2 | 0.86 | 5.65 | NA | RGS | 0.48022409 | 1 | CC | CTQ | DSM-IV |
| 45 | Seganfredo et al. (2009) - M | Seganfredo et al. (2009) - M - PN | 246 | 123 | Y | PN | 2.33 | 0.87 | 6.2 | NA | RGS | 0.50097229 | 1 | CC | CTQ | DSM-IV |
| 46 | Sugaya et al. (2012) | Sugaya et al. (2012) - PA | 43093 | NA | N | PA | 1.3 | 1.08 | 1.56 | NA | RGS | 0.09380734 | 1 | CS | CTQ | DSM-IV |
| 47 | Torgersen et al. (1986) | Torgersen et al. (1986) - SPT | 61 | 32 | Y | SPT | 0.53 | 0.17 | 1.61 | NA | CONT | 0.57351812 | 3 | CC | QwR | DSM-III |
| 48 | Vitriol et al. (2016) | Vitriol et al. (2016) - PA | 394 | NA | Y | PA | 0.9 | 0.4 | 1.4 | NA | CONT | 0.31958239 | 2 | CS | QwR | ICD-10 |
| 48 | Vitriol et al. (2016) | Vitriol et al. (2016) - SA | 394 | NA | Y | SA | 1.1 | 1.1 | 1.3 | NA | CONT | 0.04261584 | 2 | CS | QwR | ICD-11 |
| 48 | Vitriol et al. (2016) | Vitriol et al. (2016) - PAL | 394 | NA | Y | PAL | 0.9 | 0.6 | 1.4 | NA | CONT | 0.21614741 | 2 | CS | QwR | ICD-13 |
| 48 | Vitriol et al. (2016) | Vitriol et al. (2016) - SPT | 394 | NA | Y | SPT | 0.8 | 0.6 | 1.4 | NA | CONT | 0.21614741 | 2 | CS | QwR | ICD-12 |
| 48 | Vitriol et al. (2016) | Vitriol et al. (2016) - DV | 394 | NA | Y | DV | 1.5 | 0.9 | 2.3 | NA | CONT | 0.2393545 | 2 | CS | QwR | ICD-14 |
| 49 | Walker et al. (1992) | Walker et al. (1992) - SA | 100 | NA | Y | SA | 15.6 | 1.43 | 170.12 | NA | RGS | 1.21908919 | 3 | CS | QwR | DSM-III |
| 50 | Weissman et al. (2006) | Weissman et al. (2006) - PPD | 101 | 50 | N | PPD | 4.1 | 0.5 | 35.7 | NA | RGS | 1.0888515 | 1 | CC | QbS | DSM-IV |
| 53 | Zlotnick et al. (2008) | Zlotnick et al. (2008) - STE | 2359 | NA | N | STE | 11.1 | 3.2 | 38.2 | NA | CONT | 0.63257263 | 2 | CS | QwR | DSM-III-R |
| 101 | Tweed et al. (1989) | Tweed et al. (1989) - SPT | 3803 | NA | N | SPT | 4.52 | 1.83 | 11.16 | NA | CONT | 2.38010204 | 1 | CS | QwR | DSM-III |
| 102 | Ogliari et al. (2009) | Ogliari et al. (2009) - SPT | 712 | NA | N | SPT | 1.56 | 0.75 | 3.25 | NA | CONT | 0.6377551 | 1 | CS | QwR | DSM-IV |
| 103 | Kendler et al. (1992) | Kendler et al. (1992) - LOSS | 2036 | NA | N | LOSS | 2.08 | NA | NA | 0.01 | RGS | 0.80750693 | 1 | CS | QwR | DSM-III-R |

**Appendix A: original R outputs of moderator analysis**

Random Effects meta-tree (K = 93 studies);

REmrt(formula = OR ~ OR\_Mthd + Qlty + Dsgn + AV\_Msur + Comorb, data = studies\_no\_outlier, vi = SE, c = 0)

A tree with 6 terminal nodes was detected

Moderators were detected as: Qlty, AV\_Msur, Comorb

Test for Between-Subgroups Heterogeneity under RE assumption:

Qb = 122.081 (df = 5), p-value < 1e-04;

The estimate for the residual heterogeneity tau2 = 0.115;

Subgroup Meta-analysis Results:

 K g se zval pval ci.lb ci.ub

3 5 3.755 0.293 12.804 0.000 3.181 4.330 \*\*\*

5 3 4.947 0.544 9.099 0.000 3.881 6.012 \*\*\*

7 5 2.257 0.233 9.680 0.000 1.800 2.714 \*\*\*

9 45 1.664 0.094 17.703 0.000 1.480 1.848 \*\*\*

10 20 1.165 0.104 11.215 0.000 0.961 1.368 \*\*\*

11 15 2.091 0.176 11.883 0.000 1.746 2.436 \*\*\*

---

Signif. codes: 0 ‘\*\*\*’ 0.001 ‘\*\*’ 0.01 ‘\*’ 0.05 ‘.’ 0.1 ‘ ’ 1

**Appendix B: R scripts**

effect size analysis: <https://osf.io/gcwbv/>

subgroup difference analysis: <https://osf.io/sdqg9/>

moderator analysis: <https://osf.io/t6j3y/>

publication bias: <https://osf.io/4x8rd/>

**Appendix C: original R outputs of subgroup difference analysis**

============

By sociolegal categories using all data

RVE: Hierarchical Effects Model with Small-Sample Corrections

Model: OR ~ Adv\_Socio

Number of clusters = 40

Number of outcomes = 96 (min = 1 , mean = 2.4 , median = 1 , max = 7 )

Omega.sq = 0.4336752

Tau.sq = 1.090964

 Estimate StdErr t-value dfs P(|t|>) 95% CI.L 95% CI.U Sig

1 X.Intercept. 2.05882 0.296 6.9461 14.87 0.0000049 1.427 2.691 \*\*\*

2 Adv\_Sociodys -0.00721 0.374 -0.0193 19.62 0.9847997 -0.787 0.773

3 Adv\_Sociona 4.09576 1.604 2.5539 1.98 0.1264505 -2.874 11.065

4 Adv\_Socioneglect -0.48612 0.291 -1.6721 6.24 0.1435943 -1.191 0.219

---

Signif. codes: < .01 \*\*\* < .05 \*\* < .10 \*

---

Note: If df < 4, do not trust the results

> robu\_CR2 <- vcovCR(run, type = "CR2")

> # coef\_test(run, vcov = robu\_CR2, test = c("Satterthwaite", "saddlepoint"))

> coef\_test(run, vcov = robu\_CR2, cluster = s$SortID)

 Coef. Estimate SE t-stat d.f. p-val (Satt) Sig.

1 X.Intercept. 2.05882 0.296 6.9461 14.87 <0.001 \*\*\*

2 Adv\_Sociodys -0.00721 0.374 -0.0193 19.62 0.985

3 Adv\_Sociona 4.09576 1.604 2.5539 1.98 0.126

4 Adv\_Socioneglect -0.48612 0.291 -1.6721 6.24 0.144

> Wald\_test(run, constraints = constrain\_zero(c(2,4)), vcov = robu\_CR2)

 test Fstat df\_num df\_denom p\_val sig

 HTZ 1.53 2 10.4 0.261

============

By threat-deprivation dimensions using all data

RVE: Hierarchical Effects Model with Small-Sample Corrections

Model: OR ~ Adv\_Dim

Number of clusters = 40

Number of outcomes = 96 (min = 1 , mean = 2.4 , median = 1 , max = 7 )

Omega.sq = 0.06884079

Tau.sq = 1.753411

 Estimate StdErr t-value dfs P(|t|>) 95% CI.L 95% CI.U Sig

1 X.Intercept. 1.577 0.233 6.78 4.71 0.00134 0.968 2.19 \*\*\*

2 Adv\_DimM 0.916 0.491 1.87 9.72 0.09249 -0.182 2.01 \*

3 Adv\_DimT 0.636 0.359 1.77 6.23 0.12458 -0.233 1.51

---

Signif. codes: < .01 \*\*\* < .05 \*\* < .10 \*

---

Note: If df < 4, do not trust the results

> robu\_CR2 <- vcovCR(run, type = "CR2")

> # coef\_test(run, vcov = robu\_CR2, test = c("Satterthwaite", "saddlepoint"))

> coef\_test(run, vcov = robu\_CR2, cluster = s$SortID)

 Coef. Estimate SE t-stat d.f. p-val (Satt) Sig.

1 X.Intercept. 1.577 0.233 6.78 4.71 0.00134 \*\*

2 Adv\_DimM 0.916 0.491 1.87 9.72 0.09249 .

3 Adv\_DimT 0.636 0.359 1.77 6.23 0.12458

> Wald\_test(run, constraints = constrain\_zero(c(2,3)), vcov = robu\_CR2)

 test Fstat df\_num df\_denom p\_val sig

 HTZ 2.3 2 11.3 0.145

============

By sociolegal categories using data excluding 3 outliers

RVE: Hierarchical Effects Model with Small-Sample Corrections

Model: OR ~ Adv\_Socio

Number of clusters = 38

Number of outcomes = 93 (min = 1 , mean = 2.45 , median = 1 , max = 7 )

Omega.sq = 0.02684178

Tau.sq = 0.50908

 Estimate StdErr t-value dfs P(|t|>) 95% CI.L 95% CI.U Sig

1 X.Intercept. 1.790 0.183 9.783 13.50 0.000000167 1.396 2.184 \*\*\*

2 Adv\_Sociodys 0.198 0.299 0.664 17.86 0.515327379 -0.430 0.827

3 Adv\_Sociona 0.286 0.448 0.639 1.13 0.627535422 -4.036 4.608

4 Adv\_Socioneglect -0.259 0.172 -1.501 5.85 0.185147221 -0.683 0.165

---

Signif. codes: < .01 \*\*\* < .05 \*\* < .10 \*

---

Note: If df < 4, do not trust the results

> robu\_CR2 <- vcovCR(run, type = "CR2")

> # coef\_test(run, vcov = robu\_CR2, test = c("Satterthwaite", "saddlepoint"))

> coef\_test(run, vcov = robu\_CR2, cluster = s$SortID)

 Coef. Estimate SE t-stat d.f. p-val (Satt) Sig.

1 X.Intercept. 1.790 0.183 9.783 13.50 <0.001 \*\*\*

2 Adv\_Sociodys 0.198 0.299 0.664 17.86 0.515

3 Adv\_Sociona 0.286 0.448 0.639 1.13 0.628

4 Adv\_Socioneglect -0.259 0.172 -1.501 5.85 0.185

> Wald\_test(run, constraints = constrain\_zero(c(2,4)), vcov = robu\_CR2)

 test Fstat df\_num df\_denom p\_val sig

 HTZ 1.17 2 9.56 0.35

============

By threat-deprivation dimensions using data excluding 3 outliers

RVE: Hierarchical Effects Model with Small-Sample Corrections

Model: OR ~ Adv\_Dim

Number of clusters = 38

Number of outcomes = 93 (min = 1 , mean = 2.45 , median = 1 , max = 7 )

Omega.sq = 0.02692094

Tau.sq = 0.4911165

 Estimate StdErr t-value dfs P(|t|>) 95% CI.L 95% CI.U Sig

1 X.Intercept. 1.529 0.221 6.92 4.35 0.00167 0.935 2.124 \*\*\*

2 Adv\_DimM 0.593 0.381 1.55 9.53 0.15271 -0.263 1.449

3 Adv\_DimT 0.233 0.174 1.34 5.81 0.23129 -0.197 0.663

---

Signif. codes: < .01 \*\*\* < .05 \*\* < .10 \*

---

Note: If df < 4, do not trust the results

> robu\_CR2 <- vcovCR(run, type = "CR2")

> # coef\_test(run, vcov = robu\_CR2, test = c("Satterthwaite", "saddlepoint"))

> coef\_test(run, vcov = robu\_CR2, cluster = s$SortID)

 Coef. Estimate SE t-stat d.f. p-val (Satt) Sig.

1 X.Intercept. 1.529 0.221 6.92 4.35 0.00167 \*\*

2 Adv\_DimM 0.593 0.381 1.55 9.53 0.15271

3 Adv\_DimT 0.233 0.174 1.34 5.81 0.23129

> Wald\_test(run, constraints = constrain\_zero(c(2,3)), vcov = robu\_CR2)

 test Fstat df\_num df\_denom p\_val sig

 HTZ 1.2 2 10.2 0.341